64 related articles for article (PubMed ID: 33911659)
1. The association between the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio and systemic sclerosis and its complications: a systematic review and meta-analysis.
Zinellu A; Mangoni AA
Front Immunol; 2024; 15():1395993. PubMed ID: 38799443
[TBL] [Abstract][Full Text] [Related]
2. Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies.
Kaiser H; Näslund-Koch C; Kvist-Hansen A; Skov L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):303-321. PubMed ID: 38291285
[TBL] [Abstract][Full Text] [Related]
3. Association of Complete Blood Cell Count-Derived Inflammatory Biomarkers with Psoriasis and Mortality.
Zhao Y; Yang XT; Bai YP; Li LF
Clin Cosmet Investig Dermatol; 2023; 16():3267-3278. PubMed ID: 38021430
[TBL] [Abstract][Full Text] [Related]
4. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
[TBL] [Abstract][Full Text] [Related]
5. Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris.
Lee SH; Park YL; Bae Y
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902587
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis.
Hagino T; Saeki H; Kanda N
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769622
[TBL] [Abstract][Full Text] [Related]
7. Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists.
Hoffmann JHO; Knoop C; Enk A; Hadaschik EN
Acta Derm Venereol; 2021 Sep; 101(10):adv00568. PubMed ID: 34590148
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients.
Wang WM; Wu C; Gao YM; Li F; Yu XL; Jin HZ
BMC Immunol; 2021 Sep; 22(1):64. PubMed ID: 34565327
[TBL] [Abstract][Full Text] [Related]
9. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
D'Souza LS; Payette MJ
J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
[TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio.
Aktaş Karabay E; Aksu Çerman A; Demir D; Kıvanç Altunay I
Ann Dermatol; 2019 Dec; 31(6):601-610. PubMed ID: 33911659
[TBL] [Abstract][Full Text] [Related]
12. The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis.
Şener G; İnan Yuksel E; Gökdeniz O; Karaman K; Canat HD
Cureus; 2023 Aug; 15(8):e43790. PubMed ID: 37731441
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
14. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
